Shares of health-care companies were flat as traders hedged their bets ahead of earnings in the sector. Shares of biotech giant Celgene declined after it abandoned two clinical trials of a treatment for Crohn's disease and said it would not pursue a third.
-Rob Curran, firstname.lastname@example.org
Continue Reading Below
(END) Dow Jones Newswires
October 20, 2017 16:31 ET (20:31 GMT)